Laverock Therapeutics Advances CAR-T and Macrophage Programmes with Solid Tumour Data

A London-based biotechnology company has reported a set of functional milestones that bring its cancer treatment pipeline meaningfully closer to the clinic. Laverock Therapeutics, which builds therapies around a programmable gene control platform, announced results this month from in-vivo studies across two oncology programmes targeting solid tumours, a disease setting that has long resisted the advances made elsewhere in cancer treatment.

The more mature of the two, LVK201, is a CAR-T cell programme. CAR-T therapies have transformed outcomes in blood cancers over the past decade, and the technology is increasingly demonstrating its reach beyond oncology entirely. As BioFocus reported earlier this year, a single administration of CD19-targeted CAR-T therapy induced sustained, treatment-free remission across three severe autoimmune conditions simultaneously, pointing to a broader capacity for immune system recalibration that researchers are only beginning to map. But translating CAR-T success to solid tumours specifically has proven stubbornly difficult. The tumour microenvironment suppresses immune activity, engineered T-cells struggle to persist, and the safety profile of approaches that keep those cells permanently activated has been a persistent concern.

Laverock's platform attempts to address all three problems at once. Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy Annual Meeting in May, showed the technology can improve solid tumour control by hitting three distinct immunomodulatory pathways simultaneously. Crucially, because the system is designed to act only when T-cells are activated rather than continuously, the company says safety is significantly improved compared to alternative approaches. The logic is straightforward: a switch that responds to context causes less collateral damage than one left permanently on.

The second programme, LVK301, takes a different biological route. Rather than engineering T-cells, it engineers macrophages, a class of immune cell that plays a central role in how solid tumours defend themselves. Many solid tumours maintain what immunologists call a "cold" microenvironment, essentially an immunosuppressive state that prevents the body's own defences from mounting a meaningful attack. Laverock's macrophage programme has shown it can both restrict tumour growth directly and convert that cold environment to a "hot" one, reopening the tumour to immune attack. If that holds up in further studies, it would represent a meaningful contribution to one of the harder problems in oncology.

David Venables, Laverock's CEO, said the results provide "a clear route to lead programme selection and progression into non-clinical studies," adding that solid tumours "remain an area of huge unmet need for cancer patients."

Both datasets now inform the company's lead programme selection process. Laverock says it is working with partner organisations to map out non-clinical and clinical strategy, and plans to apply AI and single-cell analytical approaches, backed by over £2.2 million in recently awarded innovation grants, to accelerate platform development.

The combined milestones are a credible step forward for a relatively early-stage company. Whether the in-vivo results translate through non-clinical studies and into patients remains to be seen, as it does for all programmes at this stage. But the platform's ability to demonstrate activity across both T-cell and macrophage biology in the same tumour context is notable, and the broader momentum in CAR-T research, spanning oncology and now autoimmune disease, gives companies like Laverock a growing scientific foundation to build on.

Laverock Therapeutics is based in London, UK. Further information on the ASCGT data is available via the company's LinkedIn and website.